SilcsBio, LLC Announces Issuance of US Patent with Utility in Drug Design SoftwareJuly 12, 2018FOR IMMEDIATE RELEASE: July 12, 2018 Ken Malone SilcsBio, LLC 410.929.2305 Ken.Malone@silcsbio.com SilcsBio, LLC Announces Issuance of US Patent with Utility in Drug Design Software July 12, 2018 Baltimore, Maryland: SilcsBio, LLC (SilcsBio)...
SILCS-MC ranks top 10 on Free Energy Set 1 in the D3R Grand Challenge 2 on FXRMarch 26, 2018Grand Challenge 2 from D3R provided a farnesoid X receptor (FXR) target dataset to participants, which was used to test the performance of various computational approaches. SilcsBio’s SILCS-MC approach ranked 4th in Stage 1 and 6th in Stage 2 on...
SilcsBio, LLC Announces Release of CGenFF 2.1.0March 4, 2017Baltimore, MD, 4 March 2017 In ongoing efforts to improve the coverage of the CGenFF program, version 2.1.0 of the CGenFF program extends support to the S-P bond found in the GTP-gamma like molecules. Bonded parameters and charge-distribution along...
SilcsBio, LLC Announces Release of CGenFF 2.0.0December 27, 2016Baltimore, MD, 15 November 2016 Version 2.0.0 is the second release of CGenFF program, extending support to a larger variety of drug-like molecules to be used routinely in Computer-Aided Drug Design projects. Specifically, it improves treatment of...
New Peer Reviewed Article Demonstrates SilcsBio, LLC’s PerformanceNovember 4, 2016New Peer Reviewed Article Demonstrates SilcsBio, LLC’s Performance Baltimore, Maryland, 4 November 2016 Recently published research has found that SilcsBio’s product, single-step free energy perturbation (SSFEP), demonstrated equal or more accurate...
SilcsBio, LLC Receives Phase II NIH SBIR FundingJuly 8, 2016 FOR IMMEDIATE RELEASE: July 7, 2016 Ken Malone SilcsBio, LLC 410.929.2305 Ken.Malone@silcsbio.com SilcsBio, LLC Receives Phase II NIH SBIR Funding Baltimore, Maryland: SilcsBio, LLC announced today a $1.3 million funding award from the...